Gadolinium Contrast Agent-Induced CD163+ Ferroportin+ Osteogenic Cells in Nephrogenic Systemic Fibrosis  by Swaminathan, Sundararaman et al.
The American Journal of Pathology, Vol. 183, No. 3, September 2013ajp.amjpathol.orgCELL INJURY, REPAIR, AGING, AND APOPTOSIS
Gadolinium Contrast Agent-Induced CD163D FerroportinD
Osteogenic Cells in Nephrogenic Systemic Fibrosis
Sundararaman Swaminathan,*y Chhanda Bose,*y Sudhir V. Shah,*y Kimberly A. Hall,z and Kim M. HiattzFrom the Division of Nephrology,* Department of Internal Medicine, and the Departments of Pathology and Dermatology,z University of Arkansas for
Medical Sciences, Little Rock; and the Renal Section,y Medicine Service, Central Arkansas Veterans Healthcare System, Little Rock, ArkansasAccepted for publicationC
P
hJune 5, 2013.
Address correspondence to:
Sundararaman Swaminathan,
M.D., Division of Nephrology,
University of Virginia Health
Sciences Center, PO Box
800133, Charlottesville, VA
22908-0133. E-mail: SS4SA@
hscmail.mcc.virginia.edu.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2013.06.008Gadolinium-based contrast agents are linked to nephrogenic systemic ﬁbrosis in patients with renal
insufﬁciency. The pathology of nephrogenic systemic ﬁbrosis is characterized by abnormal tissue
repair: ﬁbrosis and ectopic ossiﬁcation. The mechanisms by which gadolinium could induce ﬁbrosis
and ossiﬁcation are not known. We examined in vitro the effect of a gadolinium-based contrast
agent on human peripheral blood mononuclear cells for phenotype and function relevant to the
pathology of nephrogenic systemic ﬁbrosis using immunoﬂuorescence, ﬂow cytometry, real-time
PCR, and osteogenic assays. We also examined tissues from patients with nephrogenic systemic
ﬁbrosis, using IHC to identify the presence of cells with phenotype induced by gadolinium.
Gadolinium contrast induced differentiation of human peripheral blood mononuclear cells into
a unique cellular phenotypedCD163þ cells expressing proteins involved in ﬁbrosis and bone
formation. These cells express ﬁbroblast growth factor (FGF)23, osteoblast transcription factors
Runt-related transcription factor 2, and osterix, and show an osteogenic phenotype in in vitro
assays. We show in vivo the presence of CD163þ/procollagen-1þ/osteocalcinþ cells in the ﬁbrotic
and calciﬁed tissues of nephrogenic systemic ﬁbrosis patients. Gadolinium contrasteinduced
CD163þ/ferroportinþ/FGF23þ cells with osteogenic potential may play a role in systemic ﬁbrosis and
ectopic ossiﬁcation in nephrogenic systemic ﬁbrosis. (Am J Pathol 2013, 183: 796e807; http://
dx.doi.org/10.1016/j.ajpath.2013.06.008)Supported by a University of Arkansas for Medical Sciences Clinical
Center for Translational Research (parent grant 1 UL1R R029884) pilot
study award, a KL2 award, a South Central VA Healthcare Network
Research Grants Program award, and by a VA Merit Review award
(S.V.S.).
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Health Sciences Center, Charlottesville, VA.Nephrogenic systemic ﬁbrosis (NSF) is a debilitating
ﬁbrosing illness observed in patients with advanced renal
insufﬁciency. Gadolinium-based contrast agent exposure
has been associated strongly with the development of
NSF.1,2 NSF is characterized by pathologic tissue repaird
ﬁbrosis, angiogenesis,3,4 and ectopic ossiﬁcation.5e8 The
cell population in NSF is phenotypically heterogeneous,9 and
the presence of osseous metaplasia is a strong histologic
predictor of NSF.10 We recently reported that gadolinium-
based contrast agents induce iron mobilization, that iron
accumulates in the tissues of NSF patients,2,11 and that NSF
is associated with calciphylaxis and increased cardiac and
vascular mortality.2,5,11 CD163 and ferroportin are markers
of alternatively activated macrophages. CD163 serves as an
endocytic receptor for heme and ferroportin is the only
known iron exporter in the body. Osteocalcin and osteo-
pontin are bone matrix proteins expressed by cells of osteo-
blast lineage, and expression of these markers by circulatingstigative Pathology.
.cells correlates with their osteogenic and mineralizing
function.12,13 The molecular and cellular mechanisms by
which gadolinium-based contrast agents trigger pathologic
ﬁbrosis, ossiﬁcation, and iron accumulation in NSF are
currently unknown. In this article, we report novel obser-
vations that a gadolinium-based contrast agent (Omniscan;
GE Healthcare, Inc., Cleveland, OH) induces CD163þ/
ferroportinþ cells with osteogenic potential in vitro and we
identify the presence of CD163þ/ferroportinþ/procollagen-
1þ/osteocalcinþ cells in the tissues of NSF patients.
Osteogenic Cells in NSFMaterials and Methods
For in vitro experiments, human peripheral blood mono-
nuclear cells (PBMCs) were obtained from Astarte Biologics
(Redmond, WA). Omniscan (gadoliniumediethylenetriamine
penta-acetic acid bismethylamide plus excess calciume
diethylenetriamine penta-acetic acid bismethylamide) was used
as the gadolinium contrast agent because it is known to be
associated with most cases of NSF.14Culture and Treatment of PBMCs
The viability of PBMCs was checked by a trypan blue dye
exclusion test. Cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) (ATCC, Manassas, VA), con-
taining 10% heat-inactivated serum (ATCC), penicillin,
streptomycin, L-glutamine (complete medium), and treated
with various doses (0.1, 0.5, and 2.5 mmol/L) of Omniscan
for 5 to 10 days. Omniscan (0.1, 0.5, and 2.5 mmol/L)
compared with controls induced signiﬁcant cell death under
serum-free conditions at 24 hours; thus, our culture condi-
tions included the addition of 10% serum. We chose these
Omniscan doses based on dose-titration experiments and
a cytotoxicity assay. Omniscan induced its effects on cell
differentiation between 5 and 10 days, with the most signif-
icant effect observed at 8 days. Therefore, we maintained all
our culture experiments for 8 days. Our controls included
cells grown with culture medium alone, without Omniscan,
and cells grown with 0.1 mmol and 0.5 mmol Omnipaque (an
iodinated contrast not associated with NSF but with osmo-
lality comparable with Omniscan). At the end of the experi-
ments, cells were washed with 1 PBS and used for the
following studies. Each study was repeated at least six times
using PBMCs obtained from different donors. Donors were
healthy males 40 to 55 years of age with diverse racial
backgrounds (African American, Hispanic, and white).Cell Viability and Cytotoxicity Assays
PBMCs were plated and treated in 96-well plates. Various
concentrations of Omniscan were added, and the viability of
adherent cells was measured at 8 days using a cell-counting
kit (CCK-8 colorimetric assay) from Dojindo Molecular
Technologies (Gaithersburg, MD). Because the absorbance
at 460 nm is proportional to the number of viable cells in the
medium, the viable cell number was determined using the
absorbance value of a previously prepared calibration curve.
The cytotoxic effect of Omniscan was evaluated by
measuring the percentage of lactate dehydrogenase released
by human PBMCs, which were seeded in 96-well micro-
plates with Roswell Park Memorial Institute (RPMI-1640)
medium containing 10% fetal bovine serum. Adherent cells
were lysed. Supernatant media were collected from these
cultures and analyzed for lactate dehydrogenase concentra-
tion using the Cytoscan Lactate DehydrogenaseThe American Journal of Pathology - ajp.amjpathol.orgCytotoxicity Assay kit from G-Biosciences (St. Louis, MO).
Cell proliferation was assessed using DAPI and Ki-67
staining.
Immunoﬂuorescence
Total PBMCs were seeded in ﬁbronectin-coated, 4-well BD
Biocoat chamber slides (Fisher Scientiﬁc, Pittsburgh, PA) at
a density of 1000 103 cells/chamber in Dulbecco’s modiﬁed
Eagle’s medium containing 10% heat-inactivated serum and
treated with various doses of Omniscan for 8 days. Immuno-
ﬂuorescence studies were performed to examine the expres-
sion of CD163, CD34, CD206, heme oxygenase-1, H-ferritin,
von Willebrand factor (CD31, Ulex lectin; Sigma-Aldrich,
St. Louis, MO), acetylated low-density lipoprotein, osteo-
calcin, osteopontin, and procollagen-1 (all from Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), and ferroportin and
ﬁbroblast growth factor (FGF)23 (Abcam, Cambridge, MA).
After treatment, cells were washed with 1 PBS and ﬁxed
with 4% neutral buffer formaldehyde for 15 minutes at room
temperature. Slides were washed with 1 PBS three times for
5 minutes each and rinsed with 100% alcohol. Nonspeciﬁc
sites were blocked by incubating the cells in 0.1% Triton X-
100 (Sigma-Aldrich) and 5% goat serum for 30 minutes at
room temperature, and slides then were washed three times
with 1 PBS for 5 minutes each. Cells were incubated with 2
to 10 mg/mL primary antibodies (described previously) and
diluted in 1%bovine serum albumin and 1 PBS at 37C for 1
hour. Cells werewashed ﬁve timeswith 1 PBS for 5minutes
each. Fluorescein isothiocyanate (FITC) or Texas red conju-
gated (Santa Cruz Biotechnology, Inc.) AlexaFluor 488 and
546 anti-goat and mouse IgG (Life Technologies, Grand
Island,NY) secondary antibodies (2 to 10mg/mL)were diluted
with 5% goat serum in 1 PBS and added to the cells and
incubated at 37C for 1 hour. Cells were incubated with
isotype-matchednonspeciﬁc antibodies for control. Cellswere
washed ﬁve times with 1 PBS for 5 minutes each and
mounted with Vectashield Mounting Media (Vector Labora-
tories, Burlingame, CA) containing DAPI for counterstaining
the nuclei. Slides were observed under a ﬂuorescence micro-
scope (Olympus America, Melville, NY).
Western Blot Analysis
SDS-PAGE was performed in 4% to 12% Bis-Tris NuPAGE
separating gel (Life Technologies). Equal amounts of protein
were loaded into each lane, and the fractionated protein was
electroblotted onto nitrocellulose membranes at 30 V for 1
hour at room temperature. Membranes were blocked in casein
blocker (Pierce Biotechnology, Rockford, IL) for 1 hour at
room temperature and then probed with primary antibodies
(anti-CD163, anti-CD206, anti-osteocalcin, anti-osteopontin,
antieprocollagen-1, anti-ferroportin, antieH-ferritin, antie
heme oxygenase-1 (all from Santa Cruz Biotechnology,
Inc.), antieTie-2 (R&D Systems, Inc., Minneapolis, MN),
and anti-CD31, anti-CD131, and anti-FGF23 (Abcam)797
Swaminathan et al(diluted to 1:1000 in casein blocker), and incubated overnight
at 4C using gentle shaking. Membranes were washed ﬁve
times (5 minutes each) with Tris-buffered saline with the
detergent Tween-20 [TBST; 20 mmol/L Tris,HCl (pH 7.6),
137 mmol/L NaCl, and 0.2% (vol/vol) Tween 20], and
incubated with horseradish-peroxidaseecoupled anti-IgG
(secondary antibody, dilution 1:2000) for 1 hour at room
temperature. Enhanced chemiluminescence (ECLþ; Amer-
sham Biosciences, Piscataway, NJ) and ﬂuorescence detec-
tion steps were followed for visualization of the bands. Bands
were quantiﬁed using a ChemiImager 5500 (a Innotech,
Corp., San Leandro, CA).
Flow Cytometry
After culture of PBMCs and treatment with gadolinium
contrast for the required time period as described earlier, cells
were analyzed for expression of various markers by ﬂow
cytometry. In brief, cells were harvested either by incubating
with trypsin EDTA solution for 5 minutes or by gentle
scratching with a cell scraper after 30 minutes of incubation
on ice and washed with cold 1 PBS. After blocking Fc-
receptors with 1 mg/mL human IgG (Sigma-Aldrich) for 20
minutes, samples were centrifuged at 200  g for 5 minutes.798Cells were washed with cold 1 cold PBS. Cell samples (0.5
 106 to 1  106 cells) were incubated on ice with sample
blocking buffer (10% mouse/goat serumþ 1% bovine serum
albumin) to block nonspeciﬁc sites. After 20 minutes of
incubation, samples were centrifuged at 200  g for 5
minutes. Cells were stained with either unconjugated or
phycoerythrin/FITC- or allophycocynin-conjugated mouse
or goat antibodies for CD163 (eBiosciences, Inc., San Diego,
CA), ferroportin, CD31, CD34, von Willebrand factor, heme
oxygenase-1, Tie-2 (R&D Systems, Inc.), procollagen-1,
osteocalcin (R&D Systems, Inc.), osteopontin, FGF23
(Santa Cruz Biotechnology, Inc.), and CD206 (Santa Cruz
Biotechnology, Inc.), 0.25 mg in 100 mL total volume of cell-
staining buffer (eBiosciences, Inc.), and incubated for 45
minutes on ice in the dark. Cell samples were washed two
times in 2 mL of staining buffer at 200  g for 5 minutes in
cold buffer. For unconjugated antibody (CD206, procollagen-
1, and FGF23), after washings, cells were incubated with
FITC-conjugated goat anti-mouse IgG (Santa Cruz Biotech-
nology, Inc.) or FITC-conjugated donkey anti-goat IgG for 45
minutes on ice in the dark. For intracellular staining, cells
were ﬁxed in cold 4% paraformaldehyde and permeabilized in
cell permeabilization buffer (Santa Cruz Biotechnology, Inc.).
For control, cells were incubated with the same amount ofFigure 1 Omniscan induces differentiation of
PBMCs into adherent cells in vitro. Human PBMCs
were cultured with and without 0.5 mmol gadoli-
nium contrast (Omniscan) for 8 days. A: Effect
of Omniscan on cell differentiation. Omniscan
induced in vitro differentiation of human PBMCs
into adherent spindled cells by day 8, compared
with PBMCs cultured without Omniscan (control;
0.5-mmol Omnipaque). In addition to being spin-
dled, Omniscan-treated cells were also plump in
appearance and some cells were fused together
(lower panel). Original magniﬁcation, 40. Scale
bar Z 100 mm. B: Effect of Omniscan on cell
proliferation. DAPI staining showed an increased
number of nuclei in Omniscan-treated cells
compared with controls. No nuclear division was
present. Ki-67/proliferating cell nuclear antigen
(PCNA) (red) staining showed only the background
stain, indicating a lack of cell proliferation. C:
Effect of Omniscan on cell cytotoxicity. Adherent
cells were lysed; supernatant media were collected
from these cultures and analyzed for released
lactate dehydrogenase (LDH). The data show no
signiﬁcant cytotoxicity at 0.1-mmol and 0.5-mmol
concentrations of Omniscan. *P < 0.05 from
control. D: Effect of Omniscan on cell viability.
PBMCs were plated and treated in 96-well plates
and incubated for 8 days with various concentra-
tions of Omniscan. Viability of the adherent cells
was measured on the eighth day. Data points
represent means  SD of six separate studies.
*P < 0.05 compared with control.
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Figure 2 Omniscan-induced cells express
procollagen-1, macrophage markers, iron metabolism
proteins, and proangiogenic markers as shown by
immunoﬂuorescence. A: Omniscan-induced, human
PBMCederived adherent cells expressed macrophage
marker-CD163 (red) as shown by immunoﬂuores-
cence. Omniscan-induced cells signiﬁcantly expressed
CD163 (red) and procollagen-1 (green) compared
with control cells (double-positive for CD163 and
procollagen-1, yellow). The majority of procollagen-
1eexpressing cells (red) did not express CD34
(green). CD34 was expressed only weakly, and by
a small number of CD163þ cells (CD34-red and
CD163-green). B: Omniscan-induced cells express
the iron metabolism proteins H-ferritin (green, top
panel; red, middle panel), hemeoxygenase-1
(HO-1) (red), and ferroportin (green). C: Compared
with control cells, Omniscan-induced cells signiﬁ-
cantly express the endothelial/pro-angiogenic
markers acetylated low-density lipoprotein (AcLDL)
(green), Ulex-lectin (red), Tie-2 (red), and von Wil-
lebrand factor (VWF) (green). Scale bars: 100mm. For
all immunostaining, appropriate controls included
secondary antibody alone and isotype controls (data
not shown).
Osteogenic Cells in NSFphycoerythrin, FITC, or allophycocynin-labeled IgG isotype
control (eBiosciences, Inc./R&D Systems or Santa Cruz
Biotechnology, Inc.). Each sample was resuspended in 0.3
mL 1 PBS and analyzed on a FACSCalibur ﬂow cytometer
(Becton, Dickinson and Co., Franklin Lakes, NJ). At least
10,000 cells were analyzed per staining. Data were analyzed
using CellQuest software (Becton, Dickinson and Co.).
Viable cells were identiﬁed by gating on forward and side
scatters. Data are shown as a logarithmic histogram or dot-
plots and expressed as mean ﬂuorescence intensity, ob-
tained from the statistical analysis of the ﬂuorescence height
and mean value of the x axis displayed by the software. Data
were obtained from ﬂow cytometry analyses from six inde-
pendent experiments.
Quantitative Real-Time PCR
Human PBMCs were cultured with different doses of
Omniscan (0.1 and 0.5 mmol). Transcript levels were
measured by a two-step, RT-PCR method. Total RNA was
extracted from the control and gadolinium contrastetreated
adherent cells by RNAqueous-4PCR kit (Ambion, Inc.,
Austin, TX). DNA synthesis was performed using a Verso
cDNA Synthesis kit from Dharmacon RNAi TechnologyThe American Journal of Pathology - ajp.amjpathol.org(Thermo Scientiﬁc, Pittsburgh, PA). Ampliﬁcation reaction
was performed with a Dharmacon (Thermo Scientiﬁc)
Solaris real-time quantitative PCR master mix, using 1 mL of
cDNA and 1.25 mL of a gene-speciﬁc Solaris primers/probe
set (CD163, procollagen-1, osteocalcin, Runt-related tran-
scription factor 2). The differential mRNA levels between
control and experimental groups were evaluated by the 2DDCt
comparative method where DCt is the difference between the
threshold cycle for target and S3 ribosomal protein or glyc-
eraldehyde-3-phosphate dehydrogenase (DCT Z Ctx-CtR),
and DDCt corresponds to the differences of DCt between
experimental and control samples (DDCtZ DCte-DCtc).
In Vitro Mineralization Assays
Cultures were seeded in ﬁbronectin-coated chamber slides
with 150 103 PBMCs or in 6-well culture plates at 5  106
cells per well in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum, 2 mmol/L
L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin,
and 0.25 mg/mL amphotericin B, and treated with 0.5 mmol/L
Omniscan for 8 days. Media were changed to the complete
differentiation medium containing low-glucose DMEM with
15%osteogenic stimulatory supplements, further supplemented799
Figure 3 Omniscan-induced cells have an osteogenic phenotype. A: Osteoblast-lineage marker expression by PBMCs treated with 0.5 mmol/L Omniscan using
immunoﬂuorescence. Omniscan-induced, human PBMC-derived adherent cells express the macrophage markers CD163 (red) and CD206 (green) as shown by
immunoﬂuorescence. Omniscan-induced cells signiﬁcantly expressed osteopontin (red), osteocalcin (red), procollagen-1 (green), and were double-positive for
osteocalcin and procollagen-1 (yellow) compared with control cells. The majority of Omniscan-induced cells expressed FGF23 (green). Scale bars: 100 mm. B: Protein
expression by Omniscan-induced cells. Western blot analysis of human PBMCs treated (T) with 0.5 mmol/L Omniscan or untreated (C) were performed using total cell
lysates from adherent cells, as described in Materials and Methods. Detection for CD163, CD206, H-ferritin, ferroportin, procollagen-1, osteocalcin (OCN), osteo-
pontin, and FGF23 expression was performed by immunoblotting. The representative blots in the ﬁgure show increased expression of these markers by Omniscan-
induced cells compared with controls. The same blots were stripped and reprobed with b-actin antibody. C: Graphic representation of densitometric scans of Western
blots. Data presented were derived from six separate experiments (donors) with or without 0.5 mmol/L Omniscan treatment, and means SEM of band intensities in
fold induction above control of representative proteins were plotted. On the plot, 1 on the x axis represents the controls. *P < 0.05, **P < 0.01 compared with
controls. D: Quantitative gene expression by Omniscan-induced cells. cDNA was synthesized from RNA isolated from Omniscan-induced adherent cells. Solaris
quantitative real-time PCR gene expression reagents (Dharmacon) were used to detect CD163, procollagen-1, ferroportin, hepcidin, Runt-related transcription factor
2 (Runx2), Osterix (OSX, SP7), and reference genes. cDNA and relative gene expression was calculated from quantiﬁcation cycle (Cq) values using a delta deltaCq. The
ﬁgure shows increased gene expression of CD163, ferroportin, procollagen-1, osteocalcin, and osteoblast transcription factors (Runx-2 and OSX) by Omniscan-
induced cells compared with controls. *P < 0.05, **P < 0.01, and ****P < 0.0001, for Omniscan-treated cells compared with controls.
Swaminathan et alwith a 3.5 mmol/L concentration of b-glycerophosphate, 108
mol/L dexamethasone, and 50 mg/mL ascorbic acid (Stemcell
Technologies, Vancouver, BC, Canada). Cultures were re-
plenished every 3 to 4 days with complete differentiation800medium for up to 5 weeks. After 3 and 5 weeks in the differ-
entiation medium, adherent cells were washed twice with 1
PBS and ﬁxed with 4% formaldehyde for 30 minutes, washed
two times with distilled water, and stained with 2% alizarin redajp.amjpathol.org - The American Journal of Pathology
Figure 4 Omniscan-induced cells expressmacrophagemarkers, procollagen-1, andproangiogenicmarkers as shownbyﬂow cytometry analysis. PBMCswere cultured
and treated with Omniscan and adherent cells were stained with monoclonal antibodies and then analyzed by ﬂow cytometry. A: Histograms show the ﬂuorescence
intensity of isotype control antibody (black line) compared with untreated (red line or green line) and Omniscan-treated (blue line) cells. The data are presented as
means  SEM (nZ 6 separate donors). B: Representative dot plots show increased CD163, CD34, and CD206 expression by Omniscan-induced cells compared with
controls. C: A graph shows the cumulative data derived from the six donors and shows the percentage of positive cells present on untreated and Omniscan-induced cells
The data are presented as means SEM. *P < 0.05, **P < 001, and ****P< 0.0001 as compared with controls.
Osteogenic Cells in NSFand von Kossa stain (Sigma-Aldrich) to detect any calciﬁed
nodules. After staining, cells were washed three times with
distilled water. Cells were visualized under a light microscope
and imageswere captured for qualitativeor quantitative analysis.
Immunohistochemistry
Ten archived, formalin-ﬁxed, parafﬁn-embedded skin biopsy
specimens diagnosed with NSF were retrieved from the
University of Arkansas forMedical Sciences dermatopathology
database. We retrieved existing autopsy tissues of patients who
died without end-stage kidney disease and NSF to obtain skin,
coronary artery, and heart controls. Immunohistochemical
stainingwasperformedonnewly cut sections forCD34,CD206,
CD163, ferroportin, procollagen-1, and osteocalcin. Some
sections were double-labeled for CD34/procollagen-1, CD34/
CD163,CD163/procollagen-1, andCD206/procollagen-1 using
the Envision Gj2 Doublestain System (Dako North America,
Inc., Carpinteria, CA). Antigen retrieval was performed and the
endogenous background activities were blocked.
Approval from the institutional review boards of the
University of Arkansas for Medical Sciences and Central
Arkansas Veterans Health Care System (Little Rock, AR)
were obtained to conduct this study. All clinical investigations
were conducted according to Declaration of Helsinki princi-
ples. Statistical analyses of the data obtained were performed
using SigmaStat from Jandel Scientiﬁc (San Rafael, CA).
Analysis of the data was performed using an unpaired two-
tailed Student’s t-test. Values are expressed as the arithmetic
mean 1 SEM. Differences in means with a P value less than
0.05 were considered statistically signiﬁcant.
Results
Omniscan-Induced Cells are Collagen-Secreting CD163/
Ferroportinþ/Osteocalcinþ/FGF23þ Cells
Omniscan (gadodiamide) treatment was not cytotoxic at the
concentrations (0.1 or 0.5 mmol) used for the study asThe American Journal of Pathology - ajp.amjpathol.orgshown by a lactate dehydrogenase release assay. However,
Omniscan (0.1, 0.5, and 2.5 mmol) induced a dose-
dependent differentiation of human PBMCs into signiﬁ-
cantly more adherent cells than controls as shown by the
increased absorbance with CCK-8 assays (Figure 1, C and
D). With light microscopy, at 8 days of culture, the number
of adherent cells was increased signiﬁcantly in PBMCs
cultured with 0.1 mmol/L (data not shown) and 0.5 mmol/L
Omniscan (these concentrations are comparable with serum
levels achieved in patients with advanced renal insufﬁciency
exposed to gadolinium contrast2 than in controls). The
morphology of adherent cells varied from spindle to polyg-
onal shape and in some areas they appeared to be in small
clusters, suggesting a fusogenic phenotype (Figure 1A).15
The effect of the iodinated contrast Omnipaque (iohexol)
(GE Healthcare, Inc.) on differentiation of PBMCs into
adherent cells was similar to controls (Figure 1A). DAPI and
Ki-67 staining did not reveal an increase in nuclear division
of the Omniscan-treated cells, suggesting that the increase in
cell numbers is due to increased cell survival rather than
proliferation (Figure 1B).
Omniscan-induced PBMC-derived adherent cells signiﬁ-
cantly expressed hematopoietic/macrophage markers CD163
and CD206 and the mesenchymal marker procollagen-1
(Figures 2A and 3A). Omnipaque did not induce expression
of these markers on adherent cells (data not shown). Dual
immunoﬂuorescence showed that many Omniscan-induced
CD163þ cells were CD34-negative (Figure 2A). Omniscan-
induced CD163þ cells expressed iron metabolism proteins
(H-ferritin, hemeoxygenase-1, and ferroportin) (Figure 2B),
angiogenic markers (acetylated low-density lipoprotein, Ulex
lectin, Tie-2, and von Willebrand factor) (Figure 2C), and
osteoblast-lineage markers (osteocalcin, osteopontin, and
FGF23) (Figure 3A). Immunoﬂuorescence data were veriﬁed
with Western blot, which conﬁrmed increased expression
of CD163, CD206, ferroportin, H-ferritin, procollagen-1,
osteocalcin, osteopontin, and FGF23 by Omniscan-induced
cells (Figure 3, B and C). Flow cytometry further conﬁrmed801
Figure 5 Omniscan-induced cells form mineralized nodules in vitro. PBMCs (150  103) were plated in ﬁbronectin-coated chamber slides or in 6-well
culture plates at 5  106 cells per well in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine,
100 U/mL penicillin, 100 mg/mL streptomycin, and 0.25 mg/mL amphotericin B, and treated with a 0.5-mmol/L concentration of Omniscan for 8 days. On day 9
the medium was removed from the wells and replaced with osteogenic differentiation medium with supplements, as mentioned in Materials and Methods.
Panels show representative light microscopic images. PBMCs on day zero (A) and after 8 days of Omniscan treatment (B). CeE: Omniscan-treated cells in
osteogenic differentiation medium for different days as indicated. Calcium deposition and mineralized nodules as detected by alizarin red (F) and with von
Kossa staining (G) after 7, 16, and 21 days, and 5 weeks in osteogenic medium. H: A high-power view showing signiﬁcantly increased calcium deposition and
mineralized nodule formation (alizarin red staining) by Omniscan-induced cells compared with controls. I: A high-power view showing signiﬁcantly increased
calcium deposition and mineralized nodule formation (brownish black by von Kossa staining) by Omniscan-induced cells compared with controls.
Swaminathan et althat Omniscan-induced CD163þ cells express CD34,
CD206, procollagen-1, CD31, CD131, erythropoietin
receptor, and Tie-2 (Figure 4).
Omniscan-Induced CD163D Cells Express Osteoblast
Transcription Factors and Have an Osteogenic
Phenotype in Vitro
Quantitative real-time PCR conﬁrmed the phenotype of
Omniscan-induced adherent cells because they expressed
signiﬁcantly more mRNA message for osteoblast tran-
scription factors (osterix and runt-related transcription factor
2), as well as for FGF23, procollagen-1, CD163, and fer-
roportin, than control cells (Figure 3D). Conﬁrming the
functional signiﬁcance of this ﬁnding, Omniscan-induced802adherent cells were able to cluster with calcium-phosphate
deposition and formed signiﬁcantly more mineralized
nodules under osteogenic conditions as detected by alizarin
red and von Kossa staining (Figure 5).
Collagen-Secreting CD163þ Osteocalcinþ Cells
Accumulate in Tissues of NSF Patients
To lend support for the pathophysiologic relevance of our
in vitro ﬁndings and to identify cells with an Omniscan-
induced phenotype, tissue biopsy specimens or autopsy
tissues of 10 NSF patients were examined and analyzed by
immunohistochemistry staining. For the control, biopsy
specimens from the end-stage renal disease patients without
NSF were used. The images to represent speciﬁc ﬁndings areajp.amjpathol.org - The American Journal of Pathology
Figure 6 CD163þ, CD34, and procollagenþ cells accumulate in the skin
of NSF patients. A: Only a small number of CD163þ cells (brown) were
present in the skin of end-stage renal disease (ESRD) patients with no NSF
control. B: CD34 staining of ESRD patient (control) skin, showing no
staining for CD34-positive cells. C: Extensive inﬁltration of spindled
CD163þ macrophages (brown) in the lesional dermis of a patient with NSF.
D: A CD163þ spindled macrophage (brown) in close juxtaposition with
a CD34þ ﬁbrocyte (red) in the dermis of a patient with NSF. In this biopsy
specimen, one of the cells was also double positive for CD163 (brown) and
CD34 (red). E: High-power view showing procollagen-1 (brown) and CD163
(brown) double-positive cells in the dermis of a NSF patient. F: A vessel-like
(V) structure in the dermis of a NSF patient lined by CD163 (brown) and
procollagen-1 (red) double-positive cells. Original magniﬁcation, 100
(A and C); 200 (B); 400 (F); 600 (D and E).
Figure 7 Ferroportinþ, osteocalcinþ, and CD31þ cell expression in the
skin of NSF patients. Extensive inﬁltration of cells expressing ferroportin
(brown) in the lesional dermis and adipose tissueof a patientwithNSF. C andD:
Osteocalcin expression (brown) by inﬁltrating cells in the dermis of NSF
patients. E: CD31 (red) expression by the inﬁltrating cells in the dermis of a NSF
patient. Original magniﬁcation, 100 (A and C); 200 (B and D);400 (E).
Osteogenic Cells in NSFshown inFigures 6, 7, and8.As shown in Figure 6, skin biopsy
specimens of patients without NSF have very few CD163þ
cells (Figure 6A) or no CD34þ cells (Figure 6B), whereas in
the skin biopsy specimens from NSF patients, numerous
dermal and subcutaneous CD163þ cells (Figure 6C) and
CD34þ cells (Figure 6D) co-expressing CD163þ were
present, and a juxtaposition between CD163þ cells and
CD34þ ﬁbrocytes (Figure 6D) was observed. These CD163þ
cells were largely spindle-shaped (similar to the morphology
observed in vitro). By using double immunostaining, we
showed that CD163þ cells were positive for procollagen-1,
conﬁrming their collagen-secreting phenotype observed
in vitro (Figure 6E). In the dermis of some NSF biopsy
specimens, vessel-like structures lined by CD163þ and pro-
collagen-1epositive cells were present (Figure 6F). CD163þ
cells expressed the iron-export protein ferroportin (Figure 7, A
and B). Many of these cells also expressed CD206 (data not
shown) and were osteocalcin-positive (Figure 7, C and D).
NSF patient biopsy specimens also showed the presence ofThe American Journal of Pathology - ajp.amjpathol.orginﬁltrating CD31þ cells in the dermis (Figure 7E). Our
immunohistochemistry results showed that in the NSF
patients, CD163þ cells were present not only in the skin but
also in other tissues. Figure 8 shows signiﬁcantly more
CD163þ cells in the intima, media, and perivascular tissues of
coronary arteries fromNSFpatients (Figure 8, B andC) than in
the coronary artery of an end-stage renal disease patient who
did not have NSF (Figure 8A). The same vessel from the
NSF patient also showed signiﬁcant intimal and medial
accumulation of osteocalcin (Figure 8C). In a deceased
patient with NSF, we observed extensive collagen-secreting
CD163þ cell inﬁltration in the myocardium (Figure 8, D and
E). We previously reported the gadolinium (344.4 mg/g and
48.9 mg/g) and iron content (207 mg/g and 354 mg/g) in this
patient’s aorta and myocardium, respectively.11 Figure 8F
shows co-expression of CD163þ and procollagenþ cells in
the lining of a vessel of the periaortic adventitia of an NSF
patient. Signiﬁcantly fewer CD163þ cells were observed in
the myocardium of patients who died without having NSF
(Figure 8, G and H).
Discussion
In this article, we present the novel observation that
Omniscan induces the development of CD163þ/ferroportinþ803
Figure 8 CD163þ, procollagenþ, and osteocalcinþ cells accumulate in
other tissues of NSF patients. A: Paucity of CD163þ cells (brown) in the
coronary artery of an end-stage renal disease patient without NSF. B:
Signiﬁcant CD163þ cells (brown) are present in the coronary artery of this
patient who died with NSF. C: The presence of CD163 (brown) and
procollagen-1 (red) double-positive cells in the aortic media and adventitia
of a patient who died with NSF.The aorta showed signiﬁcant intimal and
medial calciﬁcation. D: Myocardium of a patient who died with NSF shows
increased CD163þ cells (brown). E: A high-power view conﬁrming increased
CD163þ cells (brown) in the myocardium of a patient with NSF. F: A lining
of a vessel (V) in the periaortic adventitia of a NSF patient lined by CD163
(brown) and procollagen-1 (red) double-positive cells. Note red blood cells
in the lumen of the vessel shown. Small numbers of scattered CD163þ cells
(brown) in the myocardium of patients with end-stage renal disease (G)
and end-stage renal disease patients with head and neck cancer (H).
Original magniﬁcation: 40 (A, B, D, G, and H); 200 (C and E); 600 (F).
Swaminathan et alcells from human PBMCs in vitro. These cells express
osteogenic markers (runt-related transcription factor 2,
osteocalcin, procollagen-1, and FGF23) and angiogenic
markers (acetylated low-density lipoprotein, Ulex lectin, Tie-
2, CD31, erythropoietin receptor, and vonWillebrand factor)
and form mineralized nodules under osteogenic conditions
in vitro. The pathophysiologic relevance of these in vitro
ﬁndings is supported by our demonstration of inﬁltration of
collagen-secreting CD163þ/ferroportinþ/osteocalcinþ cells
in the dermis, subcutaneous adipose tissue, vessel wall,
perivascular adventitia, and myocardium of multiple NSF
patients, and showing that collagen-secreting CD163þ cells
line vessels in NSF patient biopsy specimens.
NSF is characterized by systemic ﬁbrosis and heterotopic
ossiﬁcation in the dermis and other tissues such as of the
heart6e8,16e18 and joints.8 The cellular mechanisms by804which gadolinium could induce systemic ﬁbrosis and ossi-
ﬁcation are unknown. Circulating Tie-2þ monocyte-derived
cells previously have been implicated in heterotopic skel-
etogenesis/ossiﬁcation of ﬁbrodysplasia ossiﬁcans progres-
sive19,20 and in bone formation related to fractured
healing.21 Our ﬁndings showing expression of osteoblast
transcription factors and bone matrix proteins in collagen-
secreting Tie-2þ/CD163þ cells in vitro, and the ability of
these cells to form mineralized nodules in vitro, suggests an
important role of Omniscan-induced cells in heterotopic
ossiﬁcation seen in NSF. This is supported by our demon-
stration of increased osteogenic cells in NSF patient biopsy
specimens. Of importance, we have observed FGF23
expression by osteogenic cells in NSF. This is a novel
observation and our ﬁndings suggest a potential contribution
from tissue osteogenic cells to FGF23 in NSF.22 FGF23
levels are associated with increased mortality, and FGF23
recently was shown to induce left ventricular hyper-
trophy.23,24 High calcium and phosphorus levels have been
implicated as risk factors in NSF. It is possible that high
endogenous calcium x phosphate product in uremic patients
might facilitate the development of osteogenic cells and thus
contribute to the pathogenesis of NSF. Our ongoing studies
with end-stage kidney disease patients also might clarify
some of these mechanisms. It is of interest that sodium
thiosulfate, a mineralization inhibitor,25 has been shown to
improve NSF.26
Circulating ﬁbrocytes have been suggested to be involved
in NSF pathogenesis.27e29 In a recent study, the addition of
Omniscan reduced the ability of the ﬁbrocyte differentiation
inhibitor serum amyloid P to decrease ﬁbrocyte differentia-
tion.28 The collagen-secreting CD163þ osteogenic cells
induced by Omniscan may represent unique cells that express
hematopoietic, mesenchymal, and endothelial markers
simultaneously and with similarities to hemosteoblasts,30,31
monocyte-derived mesenchymal progenitor cells,32 early
endothelial progenitor cells,30,31 and ﬁbrocytes.33e35 Unique
features of the Omniscan-induced osteogenic cells include
expression of endothelial markers (such as von Willebrand
factor), iron metabolism proteins, and erythropoietin recep-
tors, which are not known to be expressed by ﬁbrocytes.32,36
The experimental conditions used in our study may be
important in optimally identifying the unique effects of
Omniscan on PBMCs. We chose in vitro concentrations of
gadolinium in our experiments based on previous observa-
tions of in vivo concentrations of gadolinium present in end-
stage kidney disease patients who received Omniscan. As
noted by Joffe et al,37 elimination t1/2 of administered
gadolinium is prolonged to 34 hours in hemodialysis patients
and only 66% of the administered gadolinium contrast is
eliminated by 21 days in peritoneal dialysis patients. After
a 0.1-mmol/kg intravenous dose, serum concentrations of
gadolinium were 500 mmol/L in the ﬁrst few hours to 200 to
250 mmol/L at 24 to 48 hours after injection. In peritoneal
dialysis patients, serum gadolinium levels followed a similar
trend.ajp.amjpathol.org - The American Journal of Pathology
Osteogenic Cells in NSFWe have previously demonstrated that gadolinium
contrast induces iron mobilization in patients who develop
NSF.2 Further, we have demonstrated that iron accumulates
in the tissues of NSF patients.11 Iron is important in the
function of prolyl-4-hydroxylase and collagen synthesis and
has been implicated in ﬁbrosing disorders.38,39 Iron is
known to increase FGF23 levels.40,41 The source of iron in
NSF remains unknown. The CD163 pathway is important in
iron metabolism and iron is exported out of the cell by
ferroportin.42 Our ﬁnding demonstrates that the induction of
CD163 and ferroportin-expressing cells by gadolinium
contrast and signiﬁcant inﬁltration of CD163þ ferroportinþ
cells in NSF suggests a role for these cells in the iron
mobilization and accumulation observed in NSF.
Perivascular and myocardial inﬁltration of collagen-
secreting CD163þ cells in NSF is potentially important in
NSF outcome. Perivascular tissue may be exposed to some
of the highest concentrations of gadolinium chelate admin-
istered through intravascular routes. Thus, perivascular cells
(known to express CD163)43 and tissues may bear the
maximum consequences of gadolinium chelate and, conse-
quently, result in the preferential inﬁltration of CD163þ
cells in perivascular tissues. This is supported by recent
observations that gadolinium and iron accumulate in large
vessels11 and perivascular tissues in NSF,44 the ﬁnding of
perivascular inﬁltrates45 and perivascular ﬁbrosis46 in NSF
tissues, and by our previous observation that gadolinium
accumulates in human calciﬁc uremic arteriolopathy5 and
our current observation showing vascular, perivascular, and
myocardial accumulation of collagen-secreting CD163þ
cells. Collectively, these ﬁndings could explain the cardiac
ﬁbrosis, vascular calciﬁcation, and increased cardiac events
such as arrhythmias and death seen in NSF.11
Although our experiments provide a novel mechanism of
Omniscan toxicity, future studies will be required to investi-
gate if the intact gadolinium chelate itself (gadoliniume
diethylenetriamine penta-acetic acid bismethylamide plus
excess calciumediethylenetriamine penta-acetic acid bis-
methylamide) or the gadolinium ion dissociated from the
chelate induces the osteogenic cells. Gadolinium is known to
activate metabotropic glutamate receptors and glutamate
signaling regulates osteoblastic function.47 Also, the mecha-
nisms of persistence of the clinical phenotype of NSF years
after gadolinium contrast exposure would indicate the
potential role of uremia-associated factors (such as hyper-
phosphatemia) or its therapies in sustaining the osteogenic
cells, and would merit further investigation.48 Expression of
erythropoietin receptors by Omniscan-induced cells is
particularly intriguing because erythropoietin has been sus-
pected to be a co-factor in NSF49e51 and is known to up-
regulate ferroportin expression,52 stimulate endothelial
progenitor cell proliferation,53 and induce osteogenesis.54
We present a novel mechanism of gadolinium toxicity
potentially mediated through collagen-secreting CD163þ
ferroportinþ cells with an osteogenic potential. The ﬁndings
from our study could explain the cellular basis of majorThe American Journal of Pathology - ajp.amjpathol.orgobservations seen in NSF, namely systemic ﬁbrosis,
heterotopic ossiﬁcation, iron accumulation, and increased
cardiovascular mortality. Future studies are required to
further examine the role of these cells in NSF and other
systemic ﬁbrosing and calcifying conditions.Acknowledgments
We thank Dr. Judit Megyesi for assistance with immuno-
ﬂuorescence microscopy and Cindy Reid for technical
editing assistance.References
1. Grobner T: Gadoliniumda speciﬁc trigger for the development of
nephrogenic ﬁbrosing dermopathy and nephrogenic systemic
ﬁbrosis? Nephrol Dial Transplant 2006, 21:1104e1108
2. Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA,
Viswamitra S, Shah SV: Nephrogenic systemic ﬁbrosis, gadolinium,
and iron mobilization. N Engl J Med 2007, 357:720e722
3. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE: Nephrogenic
ﬁbrosing dermopathy. Am J Dermatopathol 2001, 23:383e393
4. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD: Nephrogenic
ﬁbrosing dermopathy: a novel cutaneous ﬁbrosing disorder in patients
with renal failure. Am J Med 2003, 114:563e572
5. Amuluru L, High W, Hiatt KM, Ranville J, Shah SV, Malik B,
Swaminathan S: Metal deposition in calciﬁc uremic arteriolopathy.
J Am Acad Dermatol 2009, 61:73e79
6. Deng A, Bilu Martin D, Spillane A, Chwalek J, Surin-Lord S,
Brooks S, Patrali J, Sina B, Gaspari A, Kao G: Nephrogenic systemic
ﬁbrosis with a spectrum of clinical and histopathological presentation:
a disorder of aberrant dermal remodeling. J Cutan Pathol 2009, 37:
204e210
7. Nagai Y, Hasegawa M, Shinmi K, Kishi C, Tsushima Y, Endo K,
Okabe K, Suzuki K, Ishikawa O: Nephrogenic systemic ﬁbrosis with
multiple calciﬁcation and osseous metaplasia. Acta Derm Venereol
2008, 88:597e600
8. Weigle JP, Broome DR: Nephrogenic systemic ﬁbrosis: chronic
imaging ﬁndings and review of the medical literature. Skeletal Radiol
2008, 37:457e464
9. Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE: Immunohis-
tochemical aspects of the ﬁbrogenic pathway in nephrogenic systemic
ﬁbrosis. Appl Immunohistochem Mol Morphol 2010, 18:448e452
10. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE:
Nephrogenic systemic ﬁbrosis: clinicopathological deﬁnition and
workup recommendations. J Am Acad Dermatol 2011, 65:
1095e1106
11. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M,
Brown HH, Shah SV: Cardiac and vascular metal deposition with
high mortality in nephrogenic systemic ﬁbrosis. Kidney Int 2008, 73:
1413e1418
12. Corna G, Campana L, Pignatti E, Castiglioni A, Tagliaﬁco E,
Bosurgi L, Campanella A, Brunelli S, Manfredi AA, Apostoli P,
Silvestri L, Camaschella C, Rovere-Querini P: Polarization dictates
iron handling by inﬂammatory and alternatively activated macro-
phages. Haematologica 2010, 95:1814e1822
13. Gössl M, Mödder UI, Atkinson EJ, Lerman A, Khosla S: Osteo-
calcin expression by circulating endothelial progenitor cells in
patients with coronary atherosclerosis. J Am Coll Cardiol 2008, 52:
1314e1325
14. Broome DR: Nephrogenic systemic ﬁbrosis associated with gadoli-
nium based contrast agents: a summary of the medical literature
reporting. Eur J Radiol 2008, 66:230e234805
Swaminathan et al15. Helming L, Gordon S: Macrophage fusion induced by IL-4 alterna-
tive activation is a multistage process involving multiple target
molecules. Eur J Immunol 2007, 37:33e42
16. Koreishi AF, Nazarian RM, Saenz AJ, Klepeis VE, McDonald AG,
Farris AB, Colvin RB, Duncan LM, Mandal RV, Kay J: Nephrogenic
systemic ﬁbrosis: a pathologic study of autopsy cases. Arch Pathol
Lab Med 2009, 133:1943e1948
17. Ruiz-Genao DP, Pascual-Lopez MP, Fraga S, Aragues M, Garcia-
Diez A: Osseous metaplasia in the setting of nephrogenic ﬁbrosing
dermopathy. J Cutan Pathol 2005, 32:172e175
18. Hershko K, Hull C, Ettefagh L, Nedorost S, Dyson S, Horn T,
Gilliam AC: A variant of nephrogenic ﬁbrosing dermopathy with
osteoclast-like giant cells: a syndrome of dysregulated matrix
remodeling? J Cutan Pathol 2004, 31:262e265
19. Suda RK, Billings PC, Egan KP, Kim JH, McCarrick-Walmsley R,
Glaser DL, Porter DL, Shore EM, Pignolo RJ: Circulating osteogenic
precursor cells in heterotopic bone formation. Stem Cells 2009, 27:
2209e2219
20. Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M,
Maidment ADA, Shore EM, Glaser DL, Goldhamer DJ,
Kaplan FS: Identiﬁcation of progenitor cells that contribute to
heterotopic skeletogenesis. J Bone Joint Surg Am 2009, 91:
652e663
21. Eghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL,
Khosla S: Circulating osteoblast-lineage cells in humans. N Engl J
Med 2005, 352:1959e1966
22. Fretellier N, Idee JM, Guerret S, Hollenbeck C, Hartmann D,
Gonzalez W, Robic C, Port M, Corot C: Clinical, biological, and skin
histopathologic effects of ionic macrocyclic and nonionic linear
gadolinium chelates in a rat model of nephrogenic systemic ﬁbrosis.
Invest Radiol 2011, 46:85e93
23. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H,
Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C,
Howritz E, Townsend RR, Anderson CA, Lash JP, Hsu CY,
Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before
parathyroid hormone and phosphate in chronic kidney disease.
Kidney Int 2011, 79:1370e1378
24. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T,
Gutierrez OM, Aguillon-Prada R, Lincold J, Hare JM, Mundel P,
Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS,
Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M,
Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D,
Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW,
Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy.
J Clin Invest 2011, 121:4393e4408
25. Hayden MR, Goldsmith DJ: Sodium thiosulfate: new hope for the
treatment of calciphylaxis. Semin Dial 2010, 23:258e262
26. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R: Neph-
rogenic systemic ﬁbrosis: a mysterious disease in patients with renal
failureerole of gadolinium-based contrast media in causation and the
beneﬁcial effect of intravenous sodium thiosulfate. Clin J Am Soc
Nephrol 2007, 2:258e263
27. Cowper SE: Nephrogenic ﬁbrosing dermopathy: the ﬁrst 6 years. Curr
Opin Rheumatol 2003, 15:785e790
28. Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu-Alfa AK,
Cowper SE, Bucala R, Gomer RH: Gadolinium-containing magnetic
resonance image contrast agent promotes ﬁbrocyte differentiation.
J Magn Reson Imaging 2009, 30:1284e1288
29. Quan TE, Cowper SE, Bucala R: The role of circulating ﬁbrocytes in
ﬁbrosis. Curr Rheumatol Rep 2006, 8:145e150
30. Rehman J, Li J, Orschell CM, March KL: Peripheral blood “endo-
thelial progenitor cells” are derived from monocyte/macrophages
and secrete angiogenic growth factors. Circulation 2003, 107:
1164e1169
31. Romagnani P, Annunziato F, Liotta F, Lazzeri E, Mazzinghi B,
Frosali F, Cosmi L, Maggi L, Lasagni L, Scheffold A, Kruger M,
Dimmeler S, Marra F, Gensini G, Maggi E, Romagnani S:806CD14þCD34 low cells with stem cell phenotypic and functional
features are the major source of circulating endothelial progenitors.
Circ Res 2005, 97:314e322
32. Cesselli D, Beltrami AP, Rigo S, Bergamin N, D’Aurizio F,
Verardo R, Piazza S, Klaric E, Fanin R, Tofoletto B, Marzinotto S,
Mariuzzi L, Finato N, PandolﬁM, Leri A, Schneider C, Beltrami CA,
Anversa P: Multipotent progenitor cells are present in human
peripheral blood. Circ Res 2009, 104:1225e1234
33. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN: Peripheral blood
ﬁbrocytes: differentiation pathway and migration to wound sites.
J Immunol 2001, 166:7556e7562
34. Chesney J, Bucala R: Peripheral blood ﬁbrocytes: mesenchymal
precursor cells and the pathogenesis of ﬁbrosis. Curr Rheumatol Rep
2000, 2:501e505
35. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC,
Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE,
Montgomery RR, Reilkoff RAS, Bucala RJ, Herzog EL: Circulating
monocytes from systemic sclerosis patients with interstitial lung
disease show an enhanced proﬁbrotic phenotype. Lab Invest 2010,
90:812e823
36. Tintut Y, Demer L: The hemosteoblast: friend or foe? Circ Res 2011,
108:1038e1039
37. Joffe P, Thomsen HS, Meusel M: Pharmacokinetics of gadodiamide
injection in patients with severe renal insufﬁciency and patients
undergoing hemodialysis or continuous ambulatory peritoneal dial-
ysis. Acta Radiol 1998, 5:491e502
38. Guzman NA, Ascari WQ, Cutroneo KR, Desnick RJ: Comparison
between avian and human prolyl 4-hydroxylases: studies on the
holomeric enzymes and their constituent subunits. J Cell Biochem
1992, 48:172e189
39. Otogawa K, Ogawa T, Shiga R, Nakatani K, Ikeda K, Nakajima Y,
Kawada N: Attenuation of acute and chronic liver injury in rats by
iron-deﬁcient diet. Am J Physiol Regul Integr Comp Physiol 2008,
294:R311eR320
40. Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H,
Fujimori A, Nishioka M, Nishi S, Fukagawa M: Effect of intra-
venous saccharated ferric oxide on serum FGF23 and mineral
metabolism in hemodialysis patients. Am J Nephrol 2011, 33:
421e426
41. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N,
Fukumoto S, Sugimoto T, Fujita: Hypophosphatemia induced
by intravenous administration of saccharated ferric oxide: another
form of FGF23-related hypophosphatemia. Bone 2009, 45:
814e816
42. Vallelian F, Schaer CA, Kaempfer T, Gehrig P, Duerst E,
Schoedon G, Schaer DJ: Glucocorticoid treatment skews human
monocyte differentiation into a hemoglobin-clearance phenotype with
enhanced heme-iron recycling and antioxidant capacity. Blood 2010,
116:5347e5356
43. Kim WK, Alvarez X, Fisher J, Bronﬁn B, Westmoreland S,
McLaurin J, Williams K: CD163 identiﬁes perivascular macrophages
in normal and viral encephalitic brains and potential precursors to
perivascular macrophages in blood. Am J Pathol 2006, 168:
822e834
44. Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M,
Seybold V, Vogt T, Banas B, Hofstaedter F, Kramer BK: Ultra-
structural evidence of dermal gadolinium deposits in a patient with
nephrogenic systemic ﬁbrosis and end-stage renal disease. Clin J Am
Soc Nephrol 2008, 3:968e975
45. Kroshinsky D, Kay J, Nazarian RM: Case records of the Massachu-
setts General Hospital. Case 37-2009. A 46-year-old woman with
chronic renal failure, leg swelling, and skin changes. N Engl J Med
2009, 361:2166e2176
46. Mendoza FA, Artlett CM, Sandorﬁ N, Latinis K, Piera-Velasquez S,
Jimenez SA: Description of 12 cases of nephrogenic ﬁbrosing
dermopathy and review of the literature. Semin Arthritis Rheum
2006, 35:238e249ajp.amjpathol.org - The American Journal of Pathology
Osteogenic Cells in NSF47. Taylor AF: Osteoblastic glutamate receptor function regulates bone
formation and resorption. J Musculoskelet Neuronal Interact 2002, 2:
285e290
48. Fretellier N, Idée JM, Bruneval P, Guerret S, Daubiné F, Jestin G,
Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O,
Mandet C, Bouzian N, Port M, Corot C: Hyperphosphataemia
sensitizes renally impaired rats to the proﬁbrotic effects of gadodia-
mide. Br J Pharmacol 2010, 165:1151e1162
49. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR,
Caplice NM, Grifﬁn MD, Leung N: Nephrogenic ﬁbrosing dermop-
athy and high-dose erythropoietin therapy. Ann Intern Med 2006,
145:234e235
50. Swaminathan S, Shah SV: New insights into nephrogenic systemic
ﬁbrosis. J Am Soc Nephrol 2007, 18:2636e2643
51. Hope TA, High WA, LeBoit PE, Chaopathomkul B, Rogut VS,
Herfkens RJ, Brasch RC: Nephrogenic systemic ﬁbrosis in ratsThe American Journal of Pathology - ajp.amjpathol.orgtreated with erythropoietin and intravenous iron. Radiology 2009,
253:390e398
52. Robach P, Recalcati S, Girelli D, Gelﬁ C, Aachmann-Andersen NJ,
Thomsen JJ, Norgaard AM, Alberghini A, Campostrini N,
Castagna A, Vigana A, Santambrogio P, Kempf T, Wollert KC,
Moutereau SP, Lundby C, Cairo G: Alterations of systemic and
muscle iron metabolism in human subjects treated with low-dose
recombinant erythropoietin. Blood 2009, 113:6707e6715
53. Bahlmann FH, de Groot K, Spandau J-M, Landry AL, Hertel B,
Duckert T, Boehm SM, Menne J, Haller H, Floser D: Erythro-
poietin regulates endothelial progenitor cells. Blood 2004, 103:
921e926
54. Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z,
Song J, Wang J, Lee CH, Sud S, Pienta KJ, Krebsbach PH,
Taichman RS: Erythropoietin couples hematopoiesis with bone
formation. PLoS One 2010, 5:e10853807
